STEMI Clinical Trial
— ELECTRA-SIRIOOfficial title:
Evaluation of Safety and Efficacy of Two Ticagrelor-based De-escalation Antiplatelet Strategies in Acute Coronary Syndrome: the Randomized, Multicenter, Double-blind ELECTRA RCT Study
The ELECTRA-SIRIO 2 study is a randomized, multicenter, double-blind, investigator-initiated clinical trial aimed to evaluate safety and efficacy of two ticagrelor-based de-escalation antiplatelet strategies in patients with acute coronary syndrome (ACS). During the hospitalization due to ACS, participants will be randomized in a 1:1:1 ratio into one of three arms: low-dose ticagrelor with aspirin (LDTA), low-dose ticagrelor with placebo (LDTP), and standard-dose ticagrelor with aspirin (SDTA), the latter being the control arm. Up to day 30, all enrolled patients will receive standard-dose ticagrelor (2x90mg) + aspirin (1x100mg). Starting from day 31 LDTA and LDTP patients will receive low-dose ticagrelor (2x60mg) + aspirin (1x100mg), SDTA - continuation of previous treatment. Starting from day 91 LDTP patients will receive low-dose ticagrelor (2x60mg) + placebo, SDTA and LDTA - continuation of previous treatment. The aim of the study is to evaluate the influence of ticagrelor maintenance dose reduction from 2x90mg to 2x60mg with or without continuation of aspirin versus dual antiplatelet therapy with standard dose ticagrelor in reducing clinically relevant bleeding and maintaining anti-ischemic efficacy in ACS patients.
Status | Recruiting |
Enrollment | 4500 |
Est. completion date | June 30, 2024 |
Est. primary completion date | June 30, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - diagnosis of STEMI or NSTEMI or unstable angina - for patients with STEMI, the following three inclusion criteria will have to be met: 1) new ST-elevation at the J-point in two contiguous leads with the cut-point =1 mm in all leads other than leads V2-V3, where the following cut-points apply: =2mm in men =40 years; =2.5 mm in men <40 years, or =1.5 mm in women regardless of age; or a new left bundle-branch block 2) the intention to perform primary PCI 3) detection of a rise and/or fall of cardiac troponin values with at least one value above the 99th percentile upper reference limit - for patients with NSTEMI or unstable angina, at least two of the following three criteria will have to be met: 1. symptoms indicating myocardial ischaemia 2. ST-segment changes on electrocardiography indicating myocardial ischaemia 3. detection of a rise and/or fall of cardiac troponin values with at least one value above the 99th percentile upper reference limit in addition to at least one of the following: 1. =60 years of age; 2. previous MI or coronary artery by-pass grafting; 3. =50% stenosis in =2 coronary arteries; 4. previous ischaemic stroke or transient ischaemic attack; 5. =50% carotid stenosis or cerebral revascularisation; 6. diabetes mellitus; 7. peripheral artery disease; 8. chronic kidney disease with glomerular filtration rate <60 mL/min. Exclusion Criteria: - contraindications to ticagrelor or/and aspirin - indications for oral anticoagulation therapy - second or third grade atrio-ventricular block - previous stent thrombosis on treatment with ticagrelor - end stage kidney disease with glomerular filtration rate <15 mL/min or on haemodialysis - administration of prasugrel during the index event - pregnancy |
Country | Name | City | State |
---|---|---|---|
Poland | Antoni Jurasz University Hospital No. 1 | Bydgoszcz |
Lead Sponsor | Collaborator |
---|---|
Collegium Medicum w Bydgoszczy | Medical Research Agency, Poland |
Poland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | BARC type 2, 3 or 5 bleeding | The primary safety composite end point of this study is the first occurrence of type 2, 3 or 5 bleeding according to the BARC criteria, occurring during the first 12 months after ACS. | 12 months after ACS | |
Primary | Death from any cause, nonfatal MI or nonfatal stroke. | The primary efficacy end point is the composite of death from any cause, first nonfatal MI, or first nonfatal stroke. | 12 months after ACS | |
Secondary | Death from any cause, nonfatal MI, nonfatal stroke, BARC type 2, 3, or 5 bleeding. | The key secondary endpoint, net clinical effect, was defined as composite of death from any cause, nonfatal MI, or nonfatal stroke, and the first occurrence of BARC type 2, 3, or 5 bleeding. | 12 months after ACS | |
Secondary | BARC type 3 or 5 bleeding | Composite of the first occurrence of type 3 or 5 bleeding according to the BARC criteria. | 12 months after ACS | |
Secondary | TIMI major or minor bleeding | Composite of the first occurrence of major or minor bleeding according to the TIMI criteria. | 12 months after ACS | |
Secondary | GUSTO moderate, severe, or life-threatening bleeding | Composite of the first occurrence of moderate, severe, or life-threatening bleeding according to the GUSTO criteria. | 12 months after ACS | |
Secondary | ISTH major bleeding | The first occurrence of major bleeding according to the ISTH criteria. | 12 months after ACS | |
Secondary | Death from any cause | Death from any cause. | 12 months after ACS | |
Secondary | Death from cardiovascular causes | Death from cardiovascular causes. | 12 months after ACS | |
Secondary | Myocardial infarction | Occurrence of myocardial infarction. | 12 months after ACS | |
Secondary | Ischemic stroke | Occurrence of ischemic stroke. | 12 months after ACS | |
Secondary | Definite or probable stent thrombosis | Occurrence of definite or probable stent thrombosis | 12 months after ACS | |
Secondary | Dyspnea | Occurrence of dyspnea | 12 months after ACS |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT02871622 -
BMX Alpha Registry: a Post-market Registry of the BioMatrix Alpha TM
|
N/A | |
Completed |
NCT01325116 -
Delayed Educational Reminders in Acute Myocardial Infarction (MI)
|
N/A | |
Completed |
NCT01452139 -
Pharmacogenetic Approach to Anti-platelet Therapy for the Treatment of ST-segment Elevation Myocardial Infarction (STEMI)
|
Phase 2/Phase 3 | |
Completed |
NCT01625104 -
Randomized Trial of a Quality Improvement Intervention to Decrease D2B Time in Primary PCI for AMI
|
N/A | |
Completed |
NCT04023266 -
A Pilot Randomized Controlled Trial of Intravenous N-acetyl Cysteine in STEMI
|
Phase 2 | |
Completed |
NCT02170103 -
Microvascular Recovery With Ultrasound in Myocardial Infarction (MRUSMI) Post PCI Trial
|
N/A | |
Completed |
NCT03103620 -
Safety and Effectiveness Evaluation of COBRA PzF Coronary Stent System: A Post Marketing Observational Registry
|
||
Not yet recruiting |
NCT05975567 -
Deploying Novel Imaging Modalities Towards a Three-dimensional (3D) CARDIOvascular PATHology
|
||
Enrolling by invitation |
NCT03328156 -
Erectile Dysfunction After Percutaneous Coronary Intervention Versus the Thrombolytic Therapy in Acute ST Elevation Myocardial Infarction
|
N/A | |
Completed |
NCT04017169 -
No Reflow Phenomenon Incidence and Predictors
|
||
Completed |
NCT03470441 -
A Study of Acute Myocardial Infarction Using FDY-5301
|
Phase 2 | |
Active, not recruiting |
NCT01433627 -
Minimizing Adverse Haemorrhagic Events by TRansradial Access Site and Systemic Implementation of angioX
|
Phase 3 | |
Completed |
NCT01197742 -
Sweetheart-Register: Risk Management of Diabetics With Acute Myocardial Infarction
|
N/A | |
Terminated |
NCT03439150 -
Resistance STEMI Study
|
N/A | |
Recruiting |
NCT03998319 -
A Study of Low-dose Intracoronary Thrombolytic Therapy in STEMI (Heart Attack) Patients.
|
Phase 3 | |
Not yet recruiting |
NCT05974930 -
Intravascular ULTRAsound-Guided PCI in Patients With ST-Elevation Myocardial Infarction
|
||
Active, not recruiting |
NCT03102723 -
Platelet Inhibition to Target Reperfusion Injury
|
Phase 2 | |
Completed |
NCT03930589 -
Remote Ischemic Conditioning in STEMI to Decrease Infarct Size
|
N/A | |
Not yet recruiting |
NCT04912167 -
The Effects of Sacubitril-Valsartan vs Enalapril on Left Ventricular Remodeling in ST-elevation Myocardial Infarction
|
Phase 3 | |
Completed |
NCT02942550 -
Methylnaltrexone as a Method to Improve Ticagrelor Uptake in Morphine Treated STEMI Patients
|
Phase 4 |